Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.

The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Ritlecitinib is effective and safe for treating alopecia areata, especially in newer cases.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

Certain cancer drugs can cause skin issues like rashes and itching.

Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Baricitinib for alopecia areata may rarely cause eye issues like keratitis.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.

Baricitinib significantly improves hair regrowth in severe alopecia areata.